The dermatology practice looks at why so many brands push peptides, and whether claims of firmer skin and fewer fine lines hold up.
Recap by typeshit. Post by @mariwalladermatology on Instagram.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Dr. Lorenc says patients ask him about peptides every week, and he pushes back on the idea that buzz on social feeds means the evidence is there.
He points to a 2025 otolaryngology study that tracked patients losing significant weight on GLP-1s and measured facial changes per 10 kg lost.
Loading…